» Articles » PMID: 35849269

Novel CD81 Mutations in a Chinese Patient Led to IgA Nephropathy and Impaired BCR Signaling

Overview
Journal J Clin Immunol
Publisher Springer
Date 2022 Jul 18
PMID 35849269
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: CD81 deficiency is an extremely rare primary immunodeficiency disease characterized by severe and recurrent infections, IgA-related nephropathy, and profound hypogammaglobulinemia. Only one patient has been reported so far, and the pathogenesis remains unclear. Here, we identified a new case of CD81 deficiency and described its pathogenesis.

Methods: We analyzed the clinical, genetic, and immunological features of the patient with CD81 deficiency, and explored the pathogenesis of her antibody deficiencies.

Results: The major manifestation of this patient was unexpectedly not recurrent infections but IgA nephropathy with aberrant serum galactose-deficient IgA1. Whole-exome sequencing revealed novel biallelic mutations in CD81 gene that abolished the surface expression of CD81. B cells from the patient lack membrane CD19 and showed reduced switched memory B cells and transitional B cells. Decreased expression of key molecules pY and pBTK in BCR signaling were demonstrated by confocal microscopy. RNA sequencing revealed that genes associated with BCR signaling and immunoglobulins were downregulated in CD81-deficient B cells. In addition, the patient showed increased frequency of T follicular helper cells that biased to Th1-like subsets.

Conclusion: We reported the second patient with CD81 deficiency in the world and illustrated aberrant BCR signaling in the patient, therefore helping to unravel the mechanism of antibody deficiency in CD81-deficient patients.

Citing Articles

IgA nephropathy in a child with X-linked agammaglobulinemia: a case report.

Song Y, Sun L, Feng D, Sun Q, Wang Y BMC Pediatr. 2024; 24(1):291.

PMID: 38689221 PMC: 11059697. DOI: 10.1186/s12887-024-04746-7.


Inborn errors of immunity in mainland China: the past, present and future.

Deng M, Mao H BMJ Paediatr Open. 2023; 7(1).

PMID: 37474202 PMC: 10357751. DOI: 10.1136/bmjpo-2023-002002.


Inborn errors of human B cell development, differentiation, and function.

Tangye S, Nguyen T, Deenick E, Bryant V, Ma C J Exp Med. 2023; 220(7).

PMID: 37273190 PMC: 10242086. DOI: 10.1084/jem.20221105.


Targeting of Tetraspanin CD81 with Monoclonal Antibodies and Small Molecules to Combat Cancers and Viral Diseases.

Bailly C, Thuru X Cancers (Basel). 2023; 15(7).

PMID: 37046846 PMC: 10093296. DOI: 10.3390/cancers15072186.

References
1.
Oren R, Takahashi S, Doss C, Levy R, Levy S . TAPA-1, the target of an antiproliferative antibody, defines a new family of transmembrane proteins. Mol Cell Biol. 1990; 10(8):4007-15. PMC: 360911. DOI: 10.1128/mcb.10.8.4007-4015.1990. View

2.
Fearon D, Carter R . The CD19/CR2/TAPA-1 complex of B lymphocytes: linking natural to acquired immunity. Annu Rev Immunol. 1995; 13:127-49. DOI: 10.1146/annurev.iy.13.040195.001015. View

3.
Carter R, Fearon D . CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes. Science. 1992; 256(5053):105-7. DOI: 10.1126/science.1373518. View

4.
Shoham T, Rajapaksa R, Boucheix C, Rubinstein E, Poe J, Tedder T . The tetraspanin CD81 regulates the expression of CD19 during B cell development in a postendoplasmic reticulum compartment. J Immunol. 2003; 171(8):4062-72. DOI: 10.4049/jimmunol.171.8.4062. View

5.
Vences-Catalan F, Kuo C, Sagi Y, Chen H, Kela-Madar N, van Zelm M . A mutation in the human tetraspanin CD81 gene is expressed as a truncated protein but does not enable CD19 maturation and cell surface expression. J Clin Immunol. 2015; 35(3):254-63. DOI: 10.1007/s10875-015-0148-2. View